Buy Trenbolone Mix 150 – HilmaBioCare EU

Product Overview & Pharmaceutical Specifications

Trenbolone Mix 150 is an injectable, oil-based sterile solution containing three trenbolone esters. According to the supplied product information, each millilitre contains a total of 150 mg of active ingredients.

Product Specifications

• Product name: Trenbolone Mix 150
• Active pharmaceutical ingredients (APIs):
  • Trenbolone acetate — 50 mg
  • Trenbolone enanthate — 50 mg
  • Trenbolone hexahydrobenzylcarbonate — 50 mg
• Total strength: 150 mg/ml
• Dosage form: Injectable, oil-based sterile solution
• Route of administration: Intramuscular (IM) injection
• Pack size: 10 ml
• Packaging: Multiple-dose vial
• CAS number supplied: 10161-33-8
• Molecular formula supplied: C18H22O2
• Molecular mass supplied: 270.366080 g/mol
• Manufacturer/company: Hilma Biocare
• Market status supplied: Prescription
• Storage conditions: 15–25°C, in a cool, dry place and protected from light

The formulation combines three trenbolone esters with different release characteristics. The supplied description states that the faster-acting ester produces a more rapid increase in serum trenbolone levels, while the slower ester provides continued elevation thereafter, with the stated duration being approximately 7–10 days.

Pharmacology & Product Information

Pharmacological Class

Trenbolone mix is described in the supplied documentation as an anabolic steroid with significant anabolic and androgenic properties. Anabolic steroids are synthetic derivatives of testosterone, and their pharmacological effects can include both anabolic and androgenic activity.

Mechanism of Action

The supplied clinical pharmacology information states that trenbolone mix binds strongly to the androgen receptor and that its principal activity is generally considered to derive from this interaction.

Exogenous anabolic-androgenic steroids can suppress gonadotropic pituitary function. According to the supplied information, administration of anabolic androgens inhibits endogenous testosterone release through suppression of pituitary luteinizing hormone (LH). At larger doses, suppression of follicle-stimulating hormone (FSH) may also affect spermatogenesis.

The supplied documentation also discusses proposed interactions involving glucocorticoid, progesterone and prolactin receptors. These mechanisms are presented in the source material as proposed or suggested pharmacological effects rather than as established clinical outcomes.

Pharmacological Context

The supplied product information describes trenbolone mix tor activity.

These pharmacological observations should not be interpreted as guarantees of a particular clinical outcome.

Documented Use in Supplied Product Information

The supplied indication describes use in adult males where substantial weight gain and increases in musculature are considered necessary for patient health following substantial losses of body mass, particularly where caloric intake is limited and other anabolic therapies have previously failed.

The source specifically states that the physician and patient must consider the risks of therapy against the potential benefits.

Pharmacokinetic Information

The supplied product description states that the faster-acting ester produces a rapid increase in serum trenbolone mix levels, while the slower-acting ester provides continued elevation thereafter for a stated duration of approximately 7–10 days.

No additional pharmacokinetic parameters, such as half-life, clearance or volume of distribution, are supplied in the source material.

Adverse Reactions & Safety Information

The supplied documentation reports the following adverse reactions and potential effects:

Male Reproductive Effects

• Gynecomastia
• Excessive frequency and duration of penile erections
• Oligospermia

Skin and Appendages

• Hirsutism
• Male-pattern baldness
• Acne
• Gynecomastia

Fluid and Electrolyte Disturbances

• Retention of sodium
• Retention of chloride
• Retention of water
• Retention of potassium
• Retention of calcium
• Retention of inorganic phosphates

Gastrointestinal and Hepatic Effects

• Nausea
• Cholestatic jaundice
• Alterations in liver function tests
• Hepatocellular neoplasms
• Peliosis hepatitis
• Hepatic adenomas
• Nephritis
• Cholestatic hepatitis

Hematologic Effects

The supplied information reports suppression of clotting factors II, V, VII and X and notes a potential for bleeding in patients receiving anticoagulant therapy.

Neurological and Psychiatric Effects

Reported effects include:

• Increased libido
• Headache
• Anxiety
• Depression
• Extreme agitation
• Irritability
• Generalized paresthesia
• Severe aggressive behaviour

Other Reported Effects

• Serum lipid changes
• Hypertension
• Hypercalcaemia
• Oedema
• Priapism
• Potentiation of sleep apnea

Drug Interactions

According to the supplied information:

• Patients receiving oral anticoagulant therapy require close monitoring, particularly when androgen therapy is started or discontinued.
• Androgens may alter the metabolism of oral hypoglycaemic agents or affect insulin sensitivity in patients with diabetes mellitus.
• Changes to insulin or other hypoglycaemic medication may therefore require medical assessment.
• Trenbolone may alter cyclosporine metabolism.
• The source advises avoiding other hepatotoxic medications.

These interaction statements should be considered together with the official prescribing information and advice from a qualified healthcare professional.

Contraindications

The supplied product information lists the following contraindications:

• Known hypersensitivity to any ingredient in the product
• Known or suspected carcinoma of the breast, testis or prostate
• Severe heart disease
• Liver disease
• Kidney disease
• History of epilepsy

The supplied documentation states that products containing androgens should not be used in women because of the potential for virilization and fetal harm.

Precautions

The source information states that women, children and elderly males should not use the product.

It further states that trenbolone should be used with extreme caution and with the lowest dosage and duration necessary for clinical response under the advice of a qualified physician.

Additional precautions supplied include:

• Caution in patients with a history of myocardial infarction or coronary artery disease because androgens may alter serum cholesterol concentrations.
• Trenbolone may increase aggressiveness and cause psychiatric changes.
• Psychiatric changes should prompt discontinuation and contact with a physician according to the supplied product information.
• Liver function should be monitored because of the stated hepatotoxicity.
• Treatment should be discontinued if signs of jaundice occur.

Patient Monitoring

The supplied documentation recommends monitoring of:

• Serum cholesterol
• HDL
• LDL
• Triglycerides (TG)
• Haemoglobin
• Haematocrit
• Hepatic function tests, including AST and ALT
• Prostate-specific antigen (PSA)
• Total testosterone
• Free testosterone
• Bioavailable testosterone
• Dihydrotestosterone (DHT)
• Estradiol
• Progesterone
• Prolactin
• Blood pressure

The source also states that male patients over 40 should undergo a digital rectal examination and PSA evaluation before androgen use. Periodic prostate evaluations are recommended during androgen therapy, particularly in patients experiencing difficulty urinating or changes in voiding habits.

Dosage & Administration

The supplied product information states:

Adult male: 50–150 mg every 3–5 days, for a duration limited to 4 weeks, under the care of a physician.

This information is reproduced from the supplied product documentation and should not be interpreted as individualized medical advice. Administration of an injectable prescription product should follow the applicable official prescribing information and the instructions of a qualified healthcare professional. TRENBOLONE MIX TRENBOLONE MIX TRENBOLONE MIX TRENBOLONE MIX TRENBOLONE MIX TRENBOLONE MIX

Presentation & Storage

Presentation: Trenbolone Mix 150 mg/ml, supplied as a 10 ml multiple-dose vial.

Storage: Store in a cool, dry place between 15–25°C. Protect from light.

Scientific & Regulatory References

No PubMed references, DOI references, clinical-literature citations, manufacturer documents or official regulatory-source links were supplied with the source material.

Accordingly, no external scientific or regulatory references have been added.

The supplied source identifies the market status as Prescription. No specific EU Member State marketing authorization, EU-wide authorization, national authorization number or regulatory approval status was supplied. Therefore, no EU-wide authorization claim is made here.

Pharmaceutical Terms & Compliance

Important: This product information is provided for informational purposes only and does not replace professional medical advice. Always consult a qualified healthcare professional and follow the official product information, prescribing instructions and applicable regulations in your country.

Trenbolone Mix 150 is identified in the supplied source as a prescription product. Regulatory requirements, authorization status, dispensing conditions and legal availability may differ between European countries. Customers should verify the applicable requirements in their jurisdiction and rely on the official prescribing information and qualified healthcare advice before use.